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Purpose: To present the first findings in the set of monozygotic twins with polypoidal 
  choroidopathy (PCV).
Methods: Sixty two-year old monozygotic twin sisters were studied. The concordances and 
discordances of the clinical features of the twins were determined. Genomic DNA was extracted 
and genotyped for three established PCV risk-associated single nucleotide polymorphisms, viz 
CFH I62V , CFH Y402H, and ARMS A69S.
Results: Both patients had hemorrhagic pigment epithelial detachments with orange lesions 
beneath the retinal pigment epithelium. Indocyanine green angiography showed pathognomonic 
choroidal vascular networks with polypoidal structures uniocularly in one twin and binocularly 
in the other twin. Both twins were treated with photodynamic therapy, retinal photocoagulation, 
and anti-vascular endothelial growth factor therapy, but both showed limited response to all the 
treatments, with recurrent exudative lesions with enlarged vascular network, and poor visual 
outcome. Genetic analyses showed that both sisters had homozygous risk alleles for ARMS2 
A69S, and one risk allele each of CFH I62V and CFH Y402H.
Conclusions: We present the first findings in a set of monozygotic twins with typical PCV 
under long-term observation. The concordances in disease progression and response to   treatment 
between the twins indicate that these genetic factors most likely played important roles in 
determining the clinical manifestations.
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Introduction
Polypoidal choroidal vasculopathy (PCV) is a sight-threatening eye disease of older 
individuals, and is characterized by dilatations at the ends of abnormal blood vessels 
in the inner choroidal vascular network.1,2 PCV is a distinct form of age-related macu-
lar degeneration (AMD). Recent studies have found similar risk factors in PCV and 
AMD.3,4 As an environmental factor, smoking is not only an established risk for AMD, 
but also for PCV .5 As genetic factors, single nucleotide polymorphisms (SNPs) of the 
complement factor H (CFH) gene6–9 and the age-related maculopathy susceptibility 
2 gene ARMS2 (also known as LOC387715)10–12 are well-documented risk factors 
for AMD.13 These risk polymorphisms are also associated with the development and 
progression of PCV .4,14–17
Monozygotic and dizygotic twins are ideal models in which to study the role of 
genes in determining the phenotype of diseases. A high concordance of the phenotypes 
in monozygotic twins would strongly suggest that genetics played a larger role in their 
development than environmental factors. Klein et al18 demonstrated a high   concordance of 
phenotype in nine pairs of monozygotic twins with AMD. Seddon et al19 demonstrated the Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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role of heredity in the development and progression of AMD 
using the largest cohort ever examined (840 male twins).
We shall present our findings in a set of monozygotic twins 
who had the characteristic features of PCV , where genetic 
analyses showed that they both carried polymorphisms of the 
CFH and ARMS2 genes. To the best of our knowledge, this 
is the first presentation of findings in a set of monozygotic 
twins with PCV under long-term observation.
Patients and methods
Patients
We studied a set of monozygotic twin sisters who were 
referred to the Retina Unit of Iwate Medical University 
Hospital. Case 1 was followed from October 2004 to 
  January 2010. Case 2 was followed from February 2004 
from to December 2009. Although Cases 1 and 2 were 
monozygotic twins, they had grown up in different families 
in different cities since birth, due to personal reasons.
Methods
Both patients received comprehensive ophthalmological 
examination, including Snellen visual acuity tests, indirect 
ophthalmoscopy, and slit-lamp examination at every visit. In 
addition, color fundus photographs, fluorescein angiography 
(FAG), and indocyanine green angiography (ICGA) were 
recorded before and after treatments.
After a full explanation of the nature of the study and the 
procedures to be used, an informed consent was obtained 
from both sisters. Genetic analysis was conducted in accor-
dance with the methods approved by the Institutional Review 
Board/Ethics Committee of the Iwate Medical University 
and Kyoto University. Genomic DNA isolations were pre-
pared with QuickGene-610L® (Fujifilm, Minato, Tokyo, 
Japan) from the patients’ peripheral blood. Genotyping for 
the three PCV-associated SNPs [rs10490924 (A69S) of the 
ARMS2 gene, and rs800292 (I62V) and rs1061170 (Y402H) 
of the CFH gene] was performed with Taqman® SNP assays 
(Applied Biosystems, Foster City, CA. USA) using NCBI 
dbSNP build 128 with the ABI PRISM® 7900HT (Applied 
Biosystems) according to the manufacturer’s instructions.
Results
Case reports
Case 1
Case 1 was 62 years old at the time of the initial examina-
tion and was the first of the twins born. She visited us in 
October 2004 with a one-month history of metamorphopsia 
and decreased vision in her right eye. She had no medical 
history and had never smoked. She weighed 58 kg and her 
body mass index (BMI) was 24.1. Her best corrected visual 
acuity (BCVA) was 25/20 in both eyes.
A hemorrhagic pigment epithelial detachment (PED) 
involving the fovea with subretinal hemorrhage inferior to the 
lower vascular arcade was detected in the right eye (Figure 1A). 
Two round orange lesions were seen beneath the retinal pig-
ment epithelium (RPE) in the   supero-  temporal region of the 
macula (Figure 1A, arrows). Fluorescein angiography (FA) 
showed dye pooling in the PED (Figure 1B). ICGA showed a 
choroidal vascular network and two polypoidal lesions at the 
edge of the PED (Figure 1C). Dye leakage from the polypoidal 
lesions was seen in the late phase of ICGA (Figure 1D).
The greatest linear dimension (GLD) of the lesion was 
3,580 µm. The choroidal vascular network and polypoidal 
lesions were treated with photodynamic therapy (PDT) with 
verteporphin (Visdyne, QLT Ophthalmics, Menlo Park, 
CA, USA). The hemorrhagic PED disappeared 3 months 
later with resolution of the metamorphopsia and retention 
of vision (Figure 1E). ICGA demonstrated closure of the 
polypoidal lesions (Figure 1F).
In March 2008, 3 years and 5 months after the initial 
PDT, a PED and subretinal hemorrhage involving the macula 
developed, with a deterioration of the BCVA to 20/100 
 ( Figure 2A). FA showed pooling of dye beneath the PED and 
leakage of dye in the macular region, suggesting the   presence 
of an occult choroidal neovascularization (Figure 2B). In the 
early phase of ICGA, abnormal   choroidal   vessels were seen 
to extend to the macula (Figure 2C, arrows).   Extensive dye 
leakage from the polypoidal structures and diffuse staining of 
the macula were seen in the late phase ICGA (Figure 2D).
Laser photocoagulation was applied to the polypoidal 
lesions at the edge of the PED, leading to the disappearance 
of the PED. However, dye leakage from the macular lesion 
further deteriorated the vision postoperatively. We injected 
bevacizumab intravitreally, which was followed by PDT. 
A GLD of 5,500 µm was observed 7 days later. Although 
the exudative changes subsided, fibrovascular tissue beneath 
the macula kept the BCVA at 20/400 (Figure 2E and 2F). 
A serous retinal detachment associated with subretinal 
  fibrosis was observed at the final visit in January 2010.
No abnormal signs were observed in the left eye fundu-
scopically and angiographically throughout the follow-up 
examinations.
Case 2
Case 2 was the second-born twin, who visited us in 
February 2004 complaining of decreased vision in the Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
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Figure 1 Case 1. Findings in a 62-year-old monozygotic twin with polypoidal choroidal vasculopathy in her right eye.
Notes: A) Fundus photograph of right eye shows a hemorrhagic pigment epithelial detachment (PeD) associated with an orange lesion beneath the retinal pigment epithelium 
(rPe) (arrows). B) Fluorescein angiogram shows dye pooling beneath the rPe. C) early phase indocyanine green angiogram (ICGA) showing a network of vessels and 
polypoidal structures. D) Late phase ICGA showing intense dye leakage from the polypoidal lesions. E) Three months after photodynamic therapy, the PeD cannot be seen. 
F) ICGA showing closure of the polypoidal lesions. 
left eye. She had never smoked, and weighed 62 kg. Her 
BMI was 25.8. She had a history of a hemorrhagic PED in 
the right eye that had been treated with photocoagulation 
when she was 57-years-old (Figure 3A). Her BCVA was 
40/50 OD and 20/60 OS. Although she had not been treated 
with   medications, serial measurements of blood pressure 
revealed that she had   systemic hypertension.
The fundus of the right eye showed chorioretinal atro-
phy induced by laser photocoagulation and RPE atrophy 
(Figure 3B). The left eye had a hemorrhagic PED   involving Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
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Figure 2 Case 1. Three years and five months after the initial photodynamic therapy (PDT).
Notes: A) Hemorrhagic pigment epithelial detachment (PeD) and subretinal hemorrhage have recurred. B) Fluorescein angiogram shows pooling of dye beneath the PeD 
and leakage of dye in the macular region. C) Indocyanine green angiogram (ICGA) delineates the polypoidal lesions and abnormal choroidal vessels that have extended from 
the treated site (arrows). D) Late phase of ICGA: extensive dye leakage from the polypoidal lesions and diffuse staining involving the macula. E) After photocoagulation 
applied to the polypoidal lesions and PDT combined with an intravitreal injection of bevacizumab: the exudative changes have subsided, leaving a subretinal fibrovascular 
tissue. F) Dye leakage from the fibrovascular tissue is still present.
the fovea which was surrounded by exudative retinal 
  detachment (Figure 3C). FA confirmed the PED as a hyper-
fluorescent area (Figure 3D). Early phase ICGA showed two 
polypoidal structures and a choroidal network of vessels with 
dye leakage in the late phase (Figures 3E and 3F).
She was treated with direct irradiation at 20 Gy to the 
posterior pole of the eye (because PDT was not available 
in Japan at that time). Three years after the irradiation, in 
March 2006, the patient was referred to us complaining of 
further deterioration of vision (to 20/200) in her left eye. Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Figure 3 Case 2. Twin sister of Case 1 with polypoidal choroidal vasculopathy in both eyes.
Notes: A, B) Fundus photographs of right eye before (A) and after (B) laser photocoagulation at the age of 57 years. C) Photograph of left fundus showing an orange lesion 
at the margin of a hemorrhagic PeD (arrows). D) Fluorescein angiogram showing leakage of dye beneath the PeD. E, F) Indocyanine green angiogram (ICGA) of right eye 
showing polypoidal lesions at the margin of the PeD (E) with late dye leakage (F). 
Examination showed an enlargement of the hemorrhagic 
PED, which was confirmed by FAG (Figure 4A and 4B). 
ICGA revealed newly-developed polypoidal structures and a 
choroidal   network of vessels (Figure 4C). ICGA-guided PDT 
was applied to the polypoidal structures and vascular network 
with two laser spots (GLD: 2,600 µm and 3,600 µm), which 
resulted in resolution of the exudative lesions and recovery 
of BCVA to 20/125 (Figure 4D).
In January 2007, 7 months after the initial PDT, exudative 
changes recurred, with reopening and further development of 
the polypoidal vascular lesions. These changes required addi-
tional treatments, including a second PDT combined with an Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Figure 4 Case 2. Three years after the direct irradiation.
Notes: A, B) Fundus photograph (A) showing the recurrence of hemorrhagic PEDs which can be seen as leakage of fluorescein in the fluorescein angiogram (B). 
C) Indocyanine green angiogram showing newly-developed polypoidal structures and network vessels. D) After PDT: the exudative changes have subsided. E, F) Fundus 
photograph (E) seven months after PDT, showing the massive subretinal hemorrhage that has developed, with further extension of the polypoidal lesions and network 
vessels (F).
intravitreal injection of bevacizumab and repeated injections 
of rabnizumab into the vitreous humor, which did not have 
favorable effects on the exudative changes. The most recent 
BCVA was 20/800. The vascular network and polypoidal 
structures had increased, with massive subretinal deposits and 
hemorrhagic PEDs (Figure 4E and 4F) in December 2009.
Genetic Variants
The genetic polymorphisms of Cases 1 and 2 are shown in 
Table 1. The twins had heterozygous gene polymorphisms 
of CFH (GA and CT for I62V and Y402H respectively). 
In addition, they had homozygous risk alleles for the ARMS2 
polymorphisms (TT for A69S).Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Discussion
We have presented the clinical and genetic findings for a set 
of monozygotic twin sisters with PCV . They had high concor-
dances in their clinical characteristics, including funduscopic 
and angiographic findings, responses to   treatments, and visual 
prognoses. In addition, they had identical PCV-susceptible 
allele distributions.
Validity of diagnosis
Both cases had pathognomonic manifestations of PCV, 
including polypoidal structures and choroidal vascular 
networks. In addition, both had orange lesions beneath the 
RPE and recurrent hemorrhagic PEDs. These clinical find-
ings were concordant with earlier descriptions of PCV .1,2 In 
the past decade, ICGA has been established as a cardinal 
diagnostic tool for PCV .2 With ICGA, our cases showed 
polypoidal structures and choroidal vascular networks that 
are characteristic of PCV .
The prevalence of PCV is high in the Asian population. 
It accounts for 24%–55% of all AMD patients.20–22 To make 
correct diagnoses of PCV in the clinics of Asia, the Japanese 
Study Group of Polypoidal Choroidal Vasculopathy pub-
lished the diagnostic criteria for PCV .23 The fundus of the 
twins showed protruded orange lesions beneath the RPE and 
polypoidal vascular lesions detected by ICGA, which meet 
the diagnostic criteria of typical PCV .
Concordances and discordances  
in clinical features
Both cases had extarafoveal vascular lesions accompa-
nied by large hemorrhagic PEDs at an early stage. With 
time, the vascular lesions enlarged and extended to the 
macular region. In addition to the typical manifestations 
of PCV , our cases shared similar clinical features such as 
size of lesion, response to treatment, and visual outcome. 
At initial visits, the responsible lesions detected by ICGA 
were relatively small and treatable by PDT. However, the 
vascular lesions progressively grew, and finally the GLD 
reached . 5,000 µm. Both twins were treated with PDT, 
which resulted in a transient resolution of the exudative 
changes and restoration of vision. However, both cases had 
recurrences of the exudative changes, which led to further 
deterioration of vision and the need for additional treatment. 
These recurrences greatly depressed the foveal function and 
finally reduced the vision to low levels.
We also found some differences in the clinical features 
between the sisters. The ocular lesion was unilateral in Case 1, 
while it was bilateral in Case 2. The ocular symptoms started 
at age 62 years in Case 1, while they started at 57 years in 
Case 2. Earlier publications have reported that environmental 
factors such as smoking,24 systemic hypertension,25 obesity,26 
and nutritional factors contribute to the development of 
AMD. Although the sisters are monozygotic twins, they 
grew up since birth in different households and in different 
cities, suggesting that environmental factors were somewhat 
different.
The BMI was slightly higher in Case 2 than in Case 1. 
In addition, Case 2 had systemic hypertension. It is possible 
that environmental factors were responsible for the pheno-
typic differences between the sisters.
Distribution of PCV-risk polymorphisms
We found three genetic polymorphism distributions in two 
genes: ARMS2 A69S and CFH I62V and Y402H. CFH is 
an essential regulatory protein that plays a critical role in 
the homeostasis of the complement system.27 The CFH gene 
variants could result in uncontrolled complement activa-
tion, which is consistent with earlier reports which suggest 
alterations of the immune system as the pathophysiology 
of AMD.28 Although the function of ARMS2 has not been 
determined, it has been shown that ARMS2 is located in the 
mitochondrial outer membrane. This would suggest that the 
ARMS2 gene variant may affect the mitochondrial function 
of photoreceptors.29
Recent studies have demonstrated significant associations 
between PCV and the genetic variants of CFH and ARMS2, 
even in the Japanese population.4,14–17 Furthermore, a combi-
nation of variants of the CFH and ARMS2 genes have been 
shown to enhance the risk of developing PCV .4 Mori et al4 
reported that the joint odds ratio for the combination of geno-
types TT for ARMS2 A69S and CT for CFH Y402H (the 
same combination seen in our twins) was 6.65. In addition, the 
homozygous risk alleles for the ARMS2 gene were reported 
to be highly associated with massive subretinal hemorrhage, 
vitreous hemorrhage, and larger lesion size in Japanese 
patients with PCV .14,17,30 Therefore, our cases had high-risk 
alleles for the development, progression, and advancement 
of PCV. In fact, our cases had repeated   recurrences and 
unfavorable visual outcomes despite treatment.
Table  1  Genetic  polymorphisms  of  CFH  and ArMs2  (LOC 
387715)
Case 1 Case 2 Risk allele
CFHI62V GA GA G
CFHY402H CT CT C
ArMs2 (LOC387715) A698 TT TT TClinical Ophthalmology
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Conclusions
We have reported the phenotypes and genotypes of a set of 
monozygotic twins with typical clinical features of PCV. 
The resemblances in the progression of the disease and 
response to treatment between the twins indicate that genetic 
factors played important roles in determining their clinical 
manifestations.
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